Hetero Group of Companies gets an acceptance from the Drug Controller-General of India (DCGI), as they have given the permission for the generic version of Gilead’s Remdesivir for the treatment of COVID-19 patients in the country as it gives a positive result. They have also agreed on manufacture and selling oral antiviral drug Favipiravir, under the brand name FabiFlu, for treatment of mild to moderate COVID-19 patients in India.
Covifor will be made available to only hospitals for giving medication to only COVID-19 patients. The drug makers acquainted that Each 100 mg (injectable) medicine will be charged between Rs. 5,000 to Rs. 6,000 and the drug is to be dispensed only after getting the consent of the patients. However it should be under the observation of a healthcare practitioner.
By – Sanyogita